Phase 1 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form and follow the study requirements
• People with a life expectancy of at least 3 months
• People who have a tumour tissue sample available for a specific protein test (called CDH17), or who are willing to have a biopsy taken at the start of the study
• People who have been diagnosed with an advanced or spreading solid tumour (confirmed by laboratory testing) that has not responded to standard treatments, could not be tolerated, or where no standard treatment options remain
• People who have at least one tumour that can be measured using standard imaging criteria
• People who have a general health score of 0 or 1 on a standard scale used by doctors to assess daily functioning (confirm with trial site)
• People whose organ function and blood clotting levels meet the study's minimum requirements (confirm with trial site)
• People of childbearing potential who are willing to use effective contraception during treatment and for 6 months after the last dose

Who may not be able to join:

• People who have more than one type of cancer
• People who have previously received a treatment that targets the CDH17 protein; received another experimental treatment, systemic steroid medications, or major surgery within 4 weeks before starting the study; received anti-cancer treatment within 3 weeks (or within a specific timeframe based on the drug used) before starting; received radiation therapy within 2 weeks before starting; or taken certain medications that strongly affect how drugs are processed by the body within 2 weeks before starting (confirm with trial site)
• People who still have side effects of Grade 2 or higher from a previous cancer treatment (confirm with trial site)
• People who have active, symptomatic cancer spread to the brain or the lining around the brain
• People with a history of serious heart disease
• People who have had a stroke, blood clot in the lungs, or a deep vein blood clot within 3 months before starting the study, or who have had clotting related to a medical port or catheter, or a clot in a surface vein
• People with a history of, or current, lung inflammation (interstitial pneumonia), severe breathing problems from chronic lung disease, serious lung dysfunction, or ongoing airway spasms
• People with poorly controlled fluid build-up around the lungs, abdomen, pelvis, or heart
• People with active Hepatitis B, Hepatitis C, or HIV infection
• People with an uncontrolled active infection (bacterial, viral, fungal, or other) that requires intravenous treatment within 2 weeks before starting the study
• People with a known allergic reaction to any ingredient in the study drug (MRG007), or who have had a severe (Grade 3 or higher) allergic reaction to a similar type of medication (monoclonal antibody) in the past
• People who the trial doctor considers unsuitable to participate for any other reason

Important: Always verify eligibility with the trial site directly before applying.